LOGIN  |  REGISTER
Terns Pharmaceuticals
Terns Pharmaceuticals

Integer to Present at Raymond James & Associates’ 46th Annual Institutional Investor Conference and KeyBanc Capital Markets Healthcare Forum

February 18, 2025 | Last Trade: US$125.59 0.72 -0.57

PLANO, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced participation at the following upcoming investor conferences.

  • Integer will participate at the 2025 Raymond James & Associates’ 46th Annual Institutional Investor Conference, to be held March 3-5, 2025, in Orlando, Florida. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present on Wednesday, March 5, 2025, at 11:00 a.m. ET.
  • Integer will participate at the 2025 KeyBanc Capital Markets Healthcare Forum, to be held virtually March 18-19, 2025. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to participate in a virtual fireside chat on Wednesday, March 19, 2025, at 9:45 a.m. ET.

A live webcast of each presentation will be accessible under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net.

Learn more about Integer at www.integer.net.

About Integer®

Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.

Investor Relations:
Andrew Senn
This email address is being protected from spambots. You need JavaScript enabled to view it.
763.951.8312 
Media Relations:
Kelly Butler
This email address is being protected from spambots. You need JavaScript enabled to view it.
469.731.6617
Terns Pharmaceuticals

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page